Page 27 - Zyme Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Avacta Group PLC, License Agreement with POINT Biopharma Inc.

License to utilise Avacta's pre|CISION FAP-sensitive activation platform for radiopharmaceuticals Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on

Avacta Submits Clinical Trial Application for AVA6000 pro-doxorubixin FAP-activated Doxorubicin prodrug Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that it has submitted a Clinical Trial Application (CTA) in the UK for a Phase 1, first-in-human, open label, dose-escalation and expansion study of its lead pre|CISION prodrug, AVA6000, in patients with locally advanced or metastatic selected solid tumours. In AVA6000, Doxorubicin has been modified with Avacta's pre|CI...

(1) CN Bio's Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients. Harnessing CN Bio's Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating...